Bridging the Knowledge Gap in CYP2C19 Polymorphisms: Optimizing Omeprazole and Escitalopram Therapy for Personalized Management of Depressive Symptoms

Tsz Chun Chung BA[1], Julisa Galan BS[1], Stephanie Jackson BA[1], Dr. Stefan Lampe, MD[1]

[1]*A.T. Still University, School of Osteopathic Medicine in Arizona, 5850 E. Still Cir, Mesa, AZ 85206*

Introduction

- Global Burden of Depressive and Anxiety Disorders:
  - Depressive and anxiety disorders are among the most prevalent mental health conditions worldwide (Strawn et al., 2020). Selective serotonin reuptake inhibitors (SSRIs), such as escitalopram, are first-line treatments (Strawn et al., 2020).
- Variability in SSRI Response:
  - Up to 50% of patients experience variable therapeutic responses or adverse effects, often requiring dose adjustments or alternative therapies (Milosavljevic et al., 2021). Genetic differences in drug metabolism, particularly involving the cytochrome P450 (CYP) enzyme system, contribute to this variability (Milosavljevic et al., 2021)
- Escitalopram and CYP2C19 Polymorphisms:
  - Primarily metabolized by CYP2C19, a highly polymorphic enzyme with over 30 gene variants (Strawn et al., 2020).
  - Loss-of-function alleles (e.g., CYP2C192 and 3) and gain-of-function alleles (e.g., CYP2C1917) significantly influence drug metabolism, plasma concentrations, and therapeutic outcomes (Milosavljevic et al., 2021).
  - Poor metabolizers (PMs): More prevalent in East Asian populations; exhibit elevated escitalopram levels, increasing risks of QTc prolongation (Milosavljevic et al., 2021).
  - Ultra-rapid metabolizers (UMs): May experience subtherapeutic drug levels, reducing efficacy (Milosavljevic et al., 2021).
  - Intermediate metabolizers (IMs): Require slower titration to avoid toxicity (CPIC, 2023).
- Co-Prescription with Proton Pump Inhibitors (PPIs):
  - PPIs, such as omeprazole, are widely prescribed for GERD and other acid-related disorders (Strawn et al., 2020). In 2019, approximately 19 million U.S. patients used PPIs, with 37.8% aged 65 and older (Strawn et al., 2020). 25% of PPI users took them for over one year, and 27% continued therapy for three years or longer (Strawn et al., 2020). Both escitalopram and omeprazole are metabolized by CYP2C19, raising concerns about drug-drug interactions (Strawn et al., 2020).
  - Co-administration can lead to competitive inhibition of CYP2C19, altering escitalopram pharmacokinetics and increasing risks of adverse effects, including sudden cardiac death (SCD) (Strawn et al., 2020).
- Study Aim:
  - Investigate the influence of CYP2C19 polymorphisms on escitalopram pharmacokinetics and therapeutic response, with a focus on co-administration with omeprazole.
  - Advocate for the integration of pharmacogenomic testing into routine clinical practice to improve safety, efficacy, and adherence in patients with depressive symptoms.

Methods

- Study Design
  - Systematic review of literature on CYP2C19 polymorphisms, escitalopram pharmacokinetics, and drug-drug interactions with omeprazole.
  - Focus on pharmacogenomic testing and risk stratification in high-risk populations (e.g., geriatric, hemodialysis).
- Literature Search
  - Databases: PubMed, Google Scholar, Embase. Keywords: "CYP2C19 polymorphisms," "escitalopram pharmacokinetics," "omeprazole interactions," "pharmacogenomics," "QTc prolongation." Timeframe: 2015–2024. Additional studies: Identified through manual reference searches.
- Inclusion Criteria
  - Studies on escitalopram pharmacokinetics and CYP2C19 polymorphisms. Data on drug-drug interactions (e.g., omeprazole). Human studies with depressive symptoms or related conditions. Information on CYP2C19 phenotypes (PMs, NMs, UMs) and clinical outcomes.
- Exclusion Criteria
  - Irrelevant to CYP2C19 or escitalopram-omeprazole interactions. Animal studies, case reports, or editorials. Insufficient data on therapeutic outcomes or adverse effects.
- Data Extraction
  - Study details: Author, year, design, population. CYP2C19 data: Alleles (CYP2C192, 3, 17), phenotypes (PMs, NMs, UMs). Outcomes: Escitalopram serum levels, efficacy (e.g., HAMD scores), adverse effects (e.g., QTc prolongation, SCD). Drug interactions: Omeprazole effects, comparison with sertraline. Pharmacogenomics: Genotype-guided dosing strategies. Risk stratification: QRS/QTc ratio, serum potassium.

Results



Figure 1. CYP2C19 phenotype frequencies vary significantly across populations, with East Asians having the highest prevalence of poor metabolizers (PMs).



Figure 2. Escitalopram clearance varies significantly by CYP2C19 phenotype, with poor metabolizers (PMs) showing the lowest clearance and highest risk of toxicity.



Figure 3. PPIs significantly increase the concentration-to-dose (C/D) ratios of citalopram, escitalopram, and sertraline, with escitalopram showing the largest increase (+93.9% with omeprazole) from Gjestad et al., 2015.

Exposure Group	SCD Events	SCD Rate (/1,000 person-years)	Hazard Ratio (HR)
Citalopram/Escitalopram + PPI	292	95.3	1.31 (1.11–1.54)
Citalopram/Escitalopram alone	448	78.6	1.22 (1.06–1.41)
Sertraline + PPI	177	78.0	1.03 (0.85–1.26)
Sertraline alone (Reference)	280	62.9	1.00

Table 1. Sudden Cardiac Death (SCD) Risk in Hemodialysis Patients: Citalopram/ Escitalopram initiators using PPIs had the highest SCD risk (HR = 1.31), followed by Citalopram/ Escitalopram initiators without PPIs (HR = 1.22). Sertraline initiators, with or without PPIs, had similar SCD risks (HR = 1.03 and 1.00, respectively). Data from Assimon et al., 2022.

Study	Population	Drug	Key Finding
2019 EHR Review	137 geriatric patients	Citalopram/ Escitalopram	No QTc prolongation; 1 SCD case (escitalopram + risperidone).
2016 Medicare Cohort	1.2M geriatric patients	Escitalopram	34% ↑ VA/SCD risk vs. non-users; risk ↓ to 4% with >12 months use.
2016 Medicare Cohort	1.2M geriatric patients	Citalopram	13% ↓ risk vs. escitalopram.
2022 Danish Registry	225 arrhythmia events	Citalopram/ Escitalopram	No ↑ risk vs. other SSRIs.

Table 2. Cardiotoxicity Risks of Citalopram and Escitalopram in Geriatric Populations

Results Cont.

Global Trends
- 28 million PPI users revealed 25% long-term use (>1 year), with 63% under 65 years old. High-dose PPIs (≥DDD) were prescribed to 65% of users, amplifying risks of CYP2C19-mediated interactions. Concurrent SSRI use is prevalent in patients with comorbid GERD and depression, particularly escitalopram, which accounts for 172,893 U.S. prescriptions between 2018 2022 (Guruge et al., 2023).

CYP2C19 Polymorphisms and Escitalopram Pharmacokinetics
- Poor Metabolizers (PMs): 2.5-fold higher escitalopram serum concentrations vs. normal metabolizers (NMs). Increased risk of QTc prolongation and sudden cardiac death (SCD). Prevalence: 15% in East Asians vs. 2–5% in Caucasians (Bousman et al., 2023; Silva et al., 2024).
- Ultra-Rapid Metabolizers (UMs): 30–50% lower drug exposure, leading to subtherapeutic levels and treatment failure. Require alternative antidepressants or dose escalation (CPIC, 2023).

Population PK Model:
- CYP2C19 Phenotypes:
  - Poor Metabolizers (PMs): CL/F = 13.2 L/h (2.5-fold higher serum concentrations).
  - Intermediate Metabolizers (IMs): 1.47-fold ↑ CL/F vs. PMs.
  - Extensive Metabolizers (EMs): 2.10-fold ↑ CL/F vs. PMs.
- Body Weight: CL/F and Vd/F increase with body weight(exponents: 0.663 and 0.774, respectively). Heavier patients require higher doses to achieve therapeutic levels.

Cardiotoxicity and Risk Stratification
- QTc Prolongation: Strongly associated with escitalopram, especially in PMs. QRS/QTc ratio <0.2 predicts arrhythmia risk (Farhat et al., 2024). Hemodialysis Patients: Serum-to-dialysate potassium gradients >4 mEq/L amplify SCD risk (Assimon et al., 2022).

Treatment-Emergent Sexual Dysfunction (TESD)
- CYP2C19 IM + PMs: Improved sexual arousal vs. NMs ($F(2,54) = 8.00$, $p < 0.001$) (Islam et al., 2024). Higher S-DCT metabolite levels correlate with worse sexual function in females ($r = -0.42$, $p = 0.004$) (Islam et al., 2024).

Drug-Drug Interactions: PPIs and SSRIs
- Omeprazole: Increases escitalopram levels by 93.9% ($P < 0.001$), elevating SCD risk by 4.5-fold in PMs (Gjestad et al., 2014; Assimon et al., 2022). Hemodialysis patients on PPIs: 443 SCD events/year vs. 216 in non-PPI users (Assimon et al., 2022).
- Sertraline: Safer alternative in PPI users: No increased SCD risk (HR = 1.03, 95% CI: 0.85–1.26) (Assimon et al., 2022).

Pediatric Considerations
- CYP2C19 Phenotypes: PMs: Require lower doses (e.g., 10 mg/day escitalopram). UMs: May need higher doses (e.g., 30 mg/day) (Strawn et al., 2019).
- Drug Interactions: Cannabinoids and PPIs increase SSRI levels, necessitating therapeutic drug monitoring (TDM) (Vaughn et al., 2021a).

Special Populations
- Geriatric Patients: Conflicting evidence exists, with EHR studies showing no QTc prolongation but Medicare data indicating 34% higher arrhythmia risk in escitalopram users.34% higher arrhythmia risk in Medicare cohorts (Assimon et al., 2022).
- Hemodialysis Patients: 20–30-fold higher SCD risk due to uremic toxins and CYP2C19 inhibition, exacerbated by PPIs and electrolyte imbalances (Assimon et al., 2022).

Pharmacogenomic Implementation
- CPIC Guidelines: PMs: 50% dose reduction (max 20 mg/day). UMs: Alternative antidepressants recommended (CPIC, 2023).
- Clinical Outcomes: Genotype-guided dosing reduces adverse events by 40% and improves remission rates by 25% (Mahajna et al., 2023).

Discussion

- CYP2C19 Polymorphisms: PMs: 2.5-fold ↑ escitalopram levels → ↑ QTc prolongation/SCD risk (Bousman et al., 2023; Silva et al., 2024). UMs: 30–50% ↓ drug exposure → treatment failure; common in Caucasians (7% UMs) (CPIC, 2023). East Asians: 15% PMs vs. 2–5% in Caucasians → higher toxicity risk.
- Drug-Drug Interactions (PPIs): Omeprazole: ↑ escitalopram levels by 93.9% → 4.5-fold ↑ SCD risk in PMs (Gjestad et al., 2015; Assimon et al., 2022). Sertraline: Safer alternative (HR = 1.03 vs. 1.31 for escitalopram + PPIs). Rabeprazole: CYP2C19-independent → preferred in high-risk patients.
- Cardiotoxicity & Risk Stratification: QTc Prolongation: QRS/QTc <0.2 predicts arrhythmia (Farhat et al., 2024). Hemodialysis: Serum-to-dialysate K+ >4 mEq/L → 443 SCD events/year (Assimon et al., 2022).
- Special Populations: Geriatric: Conflicting QTc data (34% ↑ arrhythmia risk in Medicare cohorts) (Assimon et al., 2022). Hemodialysis: 20–30-fold ↑ SCD risk due to CYP2C19 inhibition (Assimon et al., 2022).
- Pharmacogenomic Implementation: Genotype-guided dosing: ↓ adverse events by 40%, ↑ remission by 25% (Mahajna et al., 2023). CPIC Guidelines: 50% dose reduction for PMs; avoid escitalopram in UMs (CPIC, 2023).
- Limitations: Retrospective studies dominate (80%) → causal inference limited. Underrepresentation of African/Hispanic/pediatric populations. Sparse data on metabolites
- Clinical Implications: Mandate CYP2C19 testing for PMs/UMs. Avoid PPIs with escitalopram; use sertraline/rabeprazole. Monitor QRS/QTc and serum K+ in high-risk groups. Prioritize TDM in hemodialysis/geriatric patients.
- Future Directions: Prospective studies in diverse populations. Explore escitalopram metabolites' role in toxicity. Phenoconversion risk assessment (e.g., fluoxetine/paroxetine)

References Available Upon Request